PPHM : Analysis & Opinions

  1. Peregrine Results Reaffirm On-Track Revenue Projection (PPHM)

    September 9, 2016
    Peregrine can emerge as long term winner amid R&D advancements and expansion into newer variants of cancer treatment.
  2. Analyst Bullish on Peregrine Following Q2 Update

    July 22, 2015
    Following earnings and with $68 million cash on hand, Peregrine biopharmaceutical is now planning several new studies. Roth ...
  3. 3 Reasons Peregrine's Stock Could Fall (PPHM)

    June 30, 2015
    Small-cap biopharmaceutical company Peregrine Pharmaceuticals (NASDAQ: PPHM) could be sitting in the sweet spot when it ...
  4. Spotlight on Peregrine's Bavituximab Expansion (PPHM, BMY)

    June 3, 2015
    Shareholders of clinical-stage biopharmaceutical company Peregrine Pharmaceuticals (NASDAQ: PPHM) haven't fared well over ...
  5. 3 Reasons Peregrine's Stock Could Rise (PPHM)

    May 13, 2015
    Peregrine Pharmaceuticals (NASDAQ: PPHM) is a small-cap biotech stock valued at only $250 million, but if its pipeline follows ...
  6. 3 Keys to Success for Peregrine Pharmaceuticals (PPHM)

    March 20, 2015
    Buying small-cap pharmaceutical companies might be for investors the equivalent of placing a bet at a Las Vegas roulette ...
Trading Center